First Line Study of Irinotecan, Capecitabine and Oxaliplatin in Metastatic Gastric or Gastroesophageal Cancer.
Status:
Completed
Trial end date:
2018-05-18
Target enrollment:
Participant gender:
Summary
The investigators hypothesize IXO chemotherapy will have an improvement in response rate and
acceptable toxicity for uncurable metastatic gastric cancer compared to historical controls.